Compare MRTN & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRTN | EVO |
|---|---|---|
| Founded | 1946 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 895.8M |
| IPO Year | 1994 | N/A |
| Metric | MRTN | EVO |
|---|---|---|
| Price | $14.18 | $2.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 698.9K | 106.1K |
| Earning Date | 04-23-2026 | 04-08-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $1,131,455,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.12 | $0.21 |
| P/E Ratio | $65.05 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.35 | $2.31 |
| 52 Week High | $14.19 | $4.80 |
| Indicator | MRTN | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 68.77 | 49.05 |
| Support Level | $11.43 | $2.32 |
| Resistance Level | N/A | $3.75 |
| Average True Range (ATR) | 0.40 | 0.08 |
| MACD | 0.18 | 0.06 |
| Stochastic Oscillator | 93.30 | 68.04 |
Marten Transport Ltd is a temperature-sensitive and dry truckload carrier in the United States. The company specializes in transporting and distributing food and other consumer packaged goods that require a temperature-controlled or insulated environment. The company operates through four segments: Truckload, Dedicated, Intermodal, and Brokerage, generating the majority of its revenue from the Truckload segment. The Truckload segment offers a mix of regional short-haul and medium- to long-haul full-load transportation services transporting food and other consumer packaged goods.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.